Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven
by Rising Prevalence, Growing Awareness and Expected Launch of Disease
Modifying Therapies
Summary
Alzheimer’s Disease (AD) is an irreversible, progressive
neurodegenerative disease, characterized by cognitive impairment, memory
loss and functional decline. Symptoms typically begin to first occur in
patients in their mid-sixties, appearing in varying stages. The
pathological features of AD comprise histopathological changes within
the brain.
Browse Detail Report With TOC @
Mild Cognitive Impairment (MCI) is a heterogeneous condition between
normal cognition and dementia, whereby cognitive changes in mental
abilities, such as memory or thinking, are affected. Almost all cases of
AD begin with MCI, but it should be noted that not all patients with
MCI go on to develop AD.
Although there is a high degree of failure and uncertainty within the
R&D of AD drugs, the number of drugs in the pipeline is
considerable, at 559. The majority of the pipeline products are novel,
and there are only seven repositioned drugs and five generic drugs. This
shows progression in terms of the different molecules being developed
as therapeutic agents within the AD pipeline.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/105552
Reasons to buy
This report will allow you to –
- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
- Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size in four Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.
Hexa Reports is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Felton Office Plaza, 6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/
No comments:
Post a Comment